FORM 51-102F3 - MATERIAL CHANGE REPORT

1. NAME AND ADDRESS OF COMPANY

Alpha Cognition Inc. c/o 1200 – 750 West Pender Street Vancouver, BC V6C 2T8

2. <u>DATE OF MATERIAL CHANGE</u>

October 21, 2024

3. <u>NEWS RELEASE</u>

News release dated October 21, 2024 was disseminated by Stockwatch and filed on SEDAR+

4. SUMMARY OF MATERIAL CHANGE

Alpha Cognition Announces Change of Officer

5. FULL DESCRIPTION OF MATERIAL CHANGE

Alpha Cognition Inc. ("Alpha Cognition" or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, announced that Henry Du has joined Alpha Cognition as the VP of Finance and Accounting and interim Chief Financial Officer (CFO).

Prior to joining Alpha Cognition, Mr. Du was Sr. Vice President of Accounting and Administration at Amplify Surgical, a medical device company focused on developing innovative endoscopic surgical techniques and spinal implant technologies, where he led the finance and accounting functions, as well as administrative roles including HR, payroll, compliance, corporate legal, and investor relations. During his tenure there, he was instrumental in helping the company achieve consistent positive EBITDA and profitability, along with doubling average daily operating liquidity. Mr. Du was also VP of Finance and Senior Corporate Controller at HUYABIO International, a leader in globalizing Chinese pharmaceutical innovation, where he established the commercial accounting policy for the company's product launch in Japan. Prior to HUYABIO, Mr. Du served in leadership roles at Eledon Pharmaceuticals (formerly Novus Therapeutics), a publicly traded clinical-stage biopharmaceutical company, United Auto Credit, and at Avanir Pharmaceuticals.

6. RELIANCE ON SUBSECTION 7.1(2) OF NATIONAL INSTRUMENT 51-102

Not applicable

7. <u>OMITTED INFORMATION</u>

Not applicable

8. EXECUTIVE OFFICER

Michael McFadden, CEO Telephone: 1-858-344-4375

9. <u>DATE OF REPORT</u>

October 21, 2024